Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 86-94

  Moody, William E ^a   Edwards, Nicola C ^a   Madhani, Melanie ^a   Chue, Colin D ^a   Steeds, Richard P ^b   Ferro, Charles J ^b   Townend, Jonathan N ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Chronic kidney disease; Endothelial dysfunction; Flow mediated dilatation

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; NEPHRECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VASODILATION;

EID: 84863087938     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.043     Document Type: Review

References (88)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
2. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
3. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010, 375:2073-2081.
4. Van Biesen W., De Bacquer D., Verbeke F., et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007, 28:478-483.
5. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
6. Foundation N.K. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
7. Kannel W.B., Stampfer M.J., Castelli W.P., et al. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984, 108:1347-1352.
8. Cerasola G., Cottone S., Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010, 28:2357-2369.
9. Mann J.F., Yi Q.L., Gerstein H.C. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2004, S59-S62.
10. Asselbergs F.W., Diercks G.F., Hillege H.L., et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809-2816.
11. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
12. Chue C.D., Townend J.N., Steeds R.P., et al. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials 2011, 12:30.
13. Edwards N.C., Steeds R.P., Stewart P.M., et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505-512.
14. Coresh J., Longenecker J.C., Miller E.R., et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998, 9:S24-S30.
15. Kalantar-Zadeh K., Block G., Humphreys M.H., et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
16. Endemann D.H., Schiffrin E.L. Endothelial dysfunction. J Am Soc Nephrol 2004, 15:1983-1992.
17. Lilitkarntakul P., Dhaun N., Melville V., et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011, 216:217-225.
18. Wilkinson I.B., Webb D.J. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol 2001, 52:631-646.
19. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314-1319.
20. Wiesmann F., Petersen S.E., Leeson P.M., et al. Global impairment of brachial, carotid, and aortic vascular function in young smokers: direct quantification by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004, 44:2056-2064.
21. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
22. Spiro J.R., Digby J.E., Ghimire G., et al. Brachial artery low-flow-mediated constriction is increased early after coronary intervention and reduces during recovery after acute coronary syndrome: characterization of a recently described index of vascular function. Eur Heart J 2011, 32:856-866.
23. Lekakis J., Abraham P., Balbarini A., et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil 2011.
24. Delles C., Michelson G., Harazny J., et al. Impaired endothelial function of the retinal vasculature in hypertensive patients. Stroke 2004, 35:1289-1293.
25. Masoura C., Pitsavos C., Aznaouridis K., et al. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 2011, 214:129-138.
26. Chowienczyk P.J., Watts G.F., Cockcroft J.R., et al. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992, 340:1430-1432.
27. Halcox J.P., Schenke W.H., Zalos G., et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106:653-658.
28. Landmesser U., Spiekermann S., Dikalov S., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002, 106:3073-3078.
29. Gokce N., Keaney J.F., Hunter L.M., et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003, 41:1769-1775.
30. Celermajer D.S., Sorensen K.E., Georgakopoulos D., et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993, 88:2149-2155.
31. Woo K.S., Chook P., Leong H.C., et al. The impact of heavy passive smoking on arterial endothelial function in modernized Chinese. J Am Coll Cardiol 2000, 36:1228-1232.
32. Elliott T.G., Cockcroft J.R., Groop P.H., et al. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 1993, 85:687-693.
33. Schofield I., Malik R., Izzard A., et al. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002, 106:3037-3043.
34. De Ciuceis C., Porteri E., Rizzoni D., et al. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension 2011.
35. Celermajer D.S., Sorensen K.E., Bull C., et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994, 24:1468-1474.
36. Charakida M., Donald A.E., Terese M., et al. Endothelial dysfunction in childhood infection. Circulation 2005, 111:1660-1665.
37. Yeboah J., Crouse J.R., Hsu F.C., et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007, 115:2390-2397.
38. Halcox J.P., Donald A.E., Ellins E., et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 2009, 119:1005-1012.
39. Stam F., van Guldener C., Becker A., et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006, 17:537-545.
40. van Guldener C., Lambert J., Janssen M.J., et al. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 1997, 12(Suppl. 2):14-18.
41. van Guldener C., Janssen M.J., Lambert J., et al. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998, 13:1782-1786.
42. Yildiz A., Oflaz H., Pusuroglu H., et al. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis 2003, 41:616-623.
43. Luksha N., Luksha L., Carrero J.J., et al. Impaired resistance artery function in patients with end-stage renal disease. Clin Sci (Lond) 2011, 120:525-536.
44. Thambyrajah J., Landray M.J., McGlynn F.J., et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000, 83:205-209.
45. Bolton C.H., Downs L.G., Victory J.G., et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001, 16:1189-1197.
46. Yilmaz M.I., Stenvinkel P., Sonmez A., et al. Vascular health, systemic inflammation and progressive reduction in kidney function: clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant 2011.
47. Litwin M., Niemirska A. Intima-media thickness measurements in children with cardiovascular risk factors. Pediatr Nephrol 2009, 24:707-719.
48. Litwin M., Wuhl E., Jourdan C., et al. Evolution of large-vessel arteriopathy in paediatric patients with chronic kidney disease. Nephrol Dial Transplant 2008, 23:2552-2557.
49. Recio-Mayoral A., Banerjee D., Streather C., et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease - a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis 2011, 216:446-451.
50. Poggio E.D., Wang X., Greene T., et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005, 16:459-466.
51. Perticone F., Maio R., Perticone M., et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010, 122:379-384.
52. National Kidney Foundation. Vascular Dysfunction, Atherosclerosis, and Vascular Calcification: Insights and Implications in CKD; 2010. Accessed December 2010 at: http://www.kidney.org/professionals/tools/pdf/12-10-0210_LBA_Vascular_bklt_LowRes.pdf.
53. Chue C.D., Townend J.N., Steeds R.P., et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010, 96:817-823.
54. Stenvinkel P., Carrero J.J., Axelsson J., et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
55. Liabeuf S., Barreto D.V., Barreto F.C., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010, 25:1183-1191.
56. Struthers A.D., MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004, 61:663-670.
57. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212-2216.
58. Lobysheva I., Rath G., Sekkali B., et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011.
59. Zucker S., Mirza H., Conner C.E., et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998, 75:780-786.
60. Blann A.D., Belgore F.M., Constans J., et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160-1163.
61. Blann A.D., Woywodt A., Bertolini F., et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 2005, 93:228-235.
62. Yilmaz M.I., Carrero J.J., Ortiz A., et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1716-1723.
63. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
64. Cupisti A., Ghiadoni L., D'Alessandro C., et al. Soy protein diet improves endothelial dysfunction in renal transplant patients. Nephrol Dial Transplant 2007, 22:229-234.
65. Chang J.W., Lee E.K., Kim T.H., et al. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am J Nephrol 2007, 27:70-74.
66. Lu T.M., Ding Y.A., Leu H.B., et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004, 94:157-161.
67. Nanayakkara P.W., Kiefte-de Jong J.C., ter Wee P.M., et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am J Kidney Dis 2009, 53:41-50.
68. Nanayakkara P.W., van Guldener C., ter Wee P.M., et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study. Arch Intern Med 2007, 167:1262-1270.
69. Han S.H., Kang E.W., Yoon S.J., et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2011.
70. Tousoulis D., Andreou I., Tsiatas M., et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis 2011, 214:151-157.
71. Mackie F.E., Rosenberg A.R., Harmer J.A., et al. HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD) - a pilot study. Acta Paediatr 2010, 99:457-459.
72. Rizzoni D., Porteri E., Guelfi D., et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non-insulin-dependent diabetes mellitus. Circulation 2001, 103:1238-1244.
73. Savoia C., Touyz R.M., Endemann D.H., et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006, 48:271-277.
74. Yilmaz M.I., Carrero J.J., Martin-Ventura J.L., et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol 2010, 5:1174-1181.
75. Yilmaz M.I., Sonmez A., Saglam M., et al. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?. Nephrol Dial Transplant 2010, 25:3250-3256.
76. Chan D.T., Watts G.F., Irish A.B., et al. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrol Dial Transplant 2011.
77. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
78. Vukusich A., Kunstmann S., Varela C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010, 5:1380-1387.
79. Bennett-Richards K., Kattenhorn M., Donald A., et al. Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure?. Circulation 2002, 105:1810-1815.
80. Thambyrajah J., Landray M.J., McGlynn F.J., et al. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?. Circulation 2000, 102:871-875.
81. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
82. Cross J.M., Donald A.E., Nuttall S.L., et al. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure. Kidney Int 2003, 63:1433-1442.
83. Italian Group for the Study of the Survival of Myocardial Infarction Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447-455.
84. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
85. Yusuf S., Dagenais G., Pogue J., et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:154-160.
86. Jablonski K.L., Chonchol M., Pierce G.L., et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011, 57:63-69.
87. Querfeld U., Anarat A., Bayazit A.K., et al. The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. Clin J Am Soc Nephrol 2010, 5:1642-1648.
88. Moody W.E., Chue C.D., Inston N.G., et al. Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors?. J Hum Hypertens 2011.